tiprankstipranks
Advertisement
Advertisement

ANTX Stock Latest News

AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
Company AnnouncementsAN2 Therapeutics Holds 2026 Annual Stockholder Meeting
24d ago
8K
ANTX
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
PremiumCompany Announcements
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
29d ago
8K
ANTX
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
PremiumThe Fly
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
29d ago
ANTX
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
PremiumThe Fly
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
2M ago
ANTX
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
PremiumThe Fly
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
2M ago
ANTX
AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
PremiumPre-EarningsAN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
2M ago
ANTX
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
Premium
Company Announcements
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
2M ago
ANTX
AN2 Therapeutics Launches New $80 Million ATM Program
Premium
Company Announcements
AN2 Therapeutics Launches New $80 Million ATM Program
3M ago
8K
ANTX
AN2 Therapeutics files $300M mixed securities shelf
PremiumThe Fly
AN2 Therapeutics files $300M mixed securities shelf
3M ago
ANTX
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
PremiumThe Fly
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
3M ago
ANTX
AN2 Therapeutics Reprices Stock Options to Enhance Retention
PremiumCompany Announcements
AN2 Therapeutics Reprices Stock Options to Enhance Retention
3M ago
8K
ANTX
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
4M ago
ANTX
AN2 Therapeutics Announces $40 Million Private Placement Financing
PremiumCompany AnnouncementsAN2 Therapeutics Announces $40 Million Private Placement Financing
4M ago
8K
ANTX
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
Premium
The Fly
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
4M ago
ANTX
AN2 Therapeutics adjusts leadership roles and executive compensation
Premium
Company Announcements
AN2 Therapeutics adjusts leadership roles and executive compensation
5M ago
8K
ANTX
AN2 Therapeutics announces FDA clearance of OSHU IND application
PremiumThe Fly
AN2 Therapeutics announces FDA clearance of OSHU IND application
6M ago
ANTX
AN2 Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
AN2 Therapeutics Reports Q3 2025 Financial Results
8M ago
ANTX
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
PremiumThe Fly
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
8M ago
ANTX
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
PremiumThe Fly
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
8M ago
GSK
ANTX
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
PremiumCompany AnnouncementsAN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
8M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
Premium
Ratings
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
11M ago
ANTX
AN2 Therapeutics Reports Improved Financial Results
Premium
Company Announcements
AN2 Therapeutics Reports Improved Financial Results
11M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >